Selank: Legal Status in the US and What FDA Has Said

Legal status of Selank

Not allowed in compounding

Selank cannot be legally compounded ^[1]. It is not on any announced FDA advisory committee agenda ^{[6] [15]}. It was not part of the April 2026 removal from Category 2 ^[2].

FDA status

FDA placed Selank acetate in Category 2 on Sept 29, 2023 ^[5]. FDA now lists it as "nominated but withdrawn," which is outside every category ^[4]. We could not confirm when the nomination was withdrawn. Selank was not one of the 12 peptides FDA removed from Category 2 in April 2026 ^[2]. It is not in Category 1 and is not on the 503A bulks list, so a 503A pharmacy may not lawfully compound it today ^[1]. FDA says it lacks important information on Selank's safety in humans ^[4]. Our confidence in this summary is medium, because FDA has not explained Selank's path.

Advisory committee

No advisory committee review. Selank is not on the July 2026 agenda or the five-peptide list planned for before the end of February 2027 ^{[6] [15]}.

FDA-approved products

None. We found no FDA-approved drug that contains Selank.

Sports (WADA)

Selank is not named on the 2026 list ^[7]. The list's S0 class covers substances with no approval by any government health authority for human use ^[7]. Whether that class covers Selank is a judgment call, so athletes should ask their anti-doping agency before use.

What happens next

We found no pending FDA review for Selank. A new nomination or another FDA action would be needed before a pharmacy could compound it ^[9].

Checked against FDA sources on Oct 24, 2026. We update this box when FDA acts. Report a change: [email protected].

Why Selank is stuck

Most peptides in the news this year are moving through a process: an advisory committee review, a vote, then a decision by FDA. Selank is not. Here is its path so far:

• Sept 29, 2023: FDA placed Selank acetate in Category 2, the group of substances it says present significant safety risks in compounding ^[5].
• Later, on a date we could not confirm, the nomination was withdrawn. FDA's safety page now lists Selank acetate as nominated but withdrawn ^[4].
• April 2026: FDA removed 12 peptides from Category 2 and set up reviews for them. Selank was not one of the 12 ^{[2] [8]}.
• July 2026 and the planned February 2027 meeting: Selank is on neither agenda ^{[6] [3]}.

Being off every list is not the same as being allowed. A 503A pharmacy may use a bulk ingredient only if it has a USP or NF monograph, is in an FDA-approved drug, or is on FDA's bulks list ^[9]. Selank has none of these and is not in Category 1 ^[1]. Because FDA no longer sorts new nominations into its interim categories (it stopped for nominations made on or after Jan 7, 2025), a fresh nomination would not by itself put Selank in Category 1 ^[9].

What Selank is

FDA's lists name it Selank acetate, and some sources call it TP-7 ^[5]. Online sellers market it for anxiety, stress and focus. FDA has not published a briefing on Selank the way it did for the July 2026 peptides, so there is no FDA summary of its human studies to report here. We did not find a primary source we could cite for its chemistry or for any human trial, and we will add one when FDA or a peer-reviewed review we can check publishes it.

Selank vs Semax

Two related peptides, two different FDA paths (as of Oct 24, 2026)

	Selank	Semax
Category 2 in 2023	Yes [5]	Yes [5]
Removed from Category 2, April 2026	No [2]	Yes [2]
Advisory committee review	None scheduled [3]	Voted 8-5-1 in favor, July 24, 2026 [10]
Legal to compound today	No [1]	No [1]

More on the other peptide is on our Semax page.

What FDA says about safety

FDA's stated concern is short: "FDA lacks important information regarding any safety issues raised by selank acetate" when given to humans, and it notes a risk of immune reactions ^[4]. FDA has not reviewed any Selank product for quality, so buyers cannot know what a vial holds.

Selank and WADA

WADA's 2026 list does not mention Selank by name ^[7]. That is not a clearance. Its catch-all class, S0, bans pharmacologically active substances that no government health authority has approved for human therapeutic use ^[7], and an anti-doping agency decides case by case whether a product fits. If you are tested, get that answer in writing first.

What would have to happen for Selank to become legal

We found no pending FDA review ^[3]. For a pharmacy to compound it, FDA would have to add it to the bulks list by rule after a committee review, or take some other formal step ^{[9] [11]}. The interim peptide access policy sent to the White House in October 2026 has no public list of peptides, and we found no report naming Selank ^{[12] [13]}. A drug company could also seek full FDA approval; we found no public filing.

Products sold as "research use only" are not a legal route; FDA rejected that label in a 2025 warning letter ^[14]. See our peptide FDA status tracker, the legal peptide price tracker, BPC-157, FDA warning letters and our guide to wellness injections.

Selank history

• Apr 22, 2026: FDA's safety page lists Selank acetate as nominated but withdrawn. The withdrawal date is not confirmed ^[4].
• Sep 29, 2023: FDA placed Selank acetate in Category 2, citing significant safety risks ^[5].

Other peptides with no FDA review under way: CJC-1295 and ipamorelin and thymosin alpha-1. Peptides that did get a favorable vote in 2026: MOTS-c and Semax.

How we check

Selank has no FDA briefing, so this page leans on FDA's lists. On Oct 24, 2026 we searched the categories document, the safety-risk page and both advisory committee meeting pages for any mention of it ^{[1] [4] [3]}. We rate our confidence in the withdrawal timeline as medium, because FDA has not explained it. When FDA publishes anything on Selank, we will add it. Our rules are in our editorial standards.